{"protocolSection": {"identificationModule": {"nctId": "NCT01845025", "orgStudyIdInfo": {"id": "CFOR258D2416"}, "secondaryIdInfos": [{"id": "2012-004854-27", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of Safety of Foradil in Patients With Persistent Asthma", "officialTitle": "A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma."}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "TERMINATED", "whyStopped": "Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was a commercial reason and not due to any change in benefit-risk.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-05"}, "primaryCompletionDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-22", "studyFirstSubmitQcDate": "2013-04-29", "studyFirstPostDateStruct": {"date": "2013-05-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-11-10", "resultsFirstSubmitQcDate": "2017-01-30", "resultsFirstPostDateStruct": {"date": "2017-03-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-01-30", "lastUpdatePostDateStruct": {"date": "2017-03-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone propionate alone.", "detailedDescription": "This was a 26 week, double blind, randomized, active-controlled safety study of Foradil in free combination with inhaled corticosteroid versus an inhaled corticosteroid alone in adults and adolescent patients with persistent asthma. The primary objective of the study was to demonstrate that the addition of formoterol fumarate to fluticasone propionate is non-inferior to fluticasone propionate alone in terms of the risk of composite serious asthma related events (asthma-related hospitalization, asthma-related intubation, and asthma-related death). The individual components of the composite primary endpoint (i.e., asthma-related hospitalization, asthma-related intubation and asthma-related death) will be assessed as a secondary safety endpoints.\n\nThe efficacy assessment is the secondary objective."}, "conditionsModule": {"conditions": ["Persistent Asthma"], "keywords": ["Asthma", "formoterol fumarate", "Foradil", "inhaled corticosteroid", "fluticasone propionate", "safety"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 827, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "FOM 12 mcg + FP", "type": "EXPERIMENTAL", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation", "interventionNames": ["Drug: Formoterol 12 mcg", "Drug: Fluticasone propionate 100 mcg", "Drug: Fluticasone propionate 250 mcg", "Drug: Fluticasone propionate 500 mcg"]}, {"label": "fluticasone propionate (FP)", "type": "ACTIVE_COMPARATOR", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation", "interventionNames": ["Drug: Fluticasone propionate 100 mcg", "Drug: Fluticasone propionate 250 mcg", "Drug: Fluticasone propionate 500 mcg", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Formoterol 12 mcg", "description": "Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler", "armGroupLabels": ["FOM 12 mcg + FP"], "otherNames": ["FOR258"]}, {"type": "DRUG", "name": "Fluticasone propionate 100 mcg", "description": "Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler", "armGroupLabels": ["FOM 12 mcg + FP", "fluticasone propionate (FP)"]}, {"type": "DRUG", "name": "Fluticasone propionate 250 mcg", "description": "Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler", "armGroupLabels": ["FOM 12 mcg + FP", "fluticasone propionate (FP)"]}, {"type": "DRUG", "name": "Fluticasone propionate 500 mcg", "description": "Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler", "armGroupLabels": ["FOM 12 mcg + FP", "fluticasone propionate (FP)"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo to match formoterol one inhalation twice daily via dry powder inhaler", "armGroupLabels": ["fluticasone propionate (FP)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks", "description": "The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 \\* n patients with any events / total N patients in treatment group.", "timeFrame": "26 weeks"}], "secondaryOutcomes": [{"measure": "Number of Asthma Exacerbations at 26 Weeks", "description": "Number of asthma exacerbations events", "timeFrame": "26 weeks"}, {"measure": "Percentage of Days of School/Work Missed at 26 Weeks", "description": "The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.", "timeFrame": "26 weeks"}, {"measure": "Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks", "description": "The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.", "timeFrame": "26 weeks"}, {"measure": "Percentage of Days With Nighttime Awakenings at 26 Weeks", "description": "Percentage of days with nighttime awakenings during the treatment period (26 weeks)", "timeFrame": "26 weeks"}, {"measure": "Percentage of Days With no Rescue Medication Use at 26 Weeks", "description": "Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.", "timeFrame": "26 weeks"}, {"measure": "Percentage of Days With no Symptoms at 26 Weeks", "description": "Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.", "timeFrame": "26 weeks"}, {"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26", "description": "Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.", "timeFrame": "baseline and 26 weeks"}, {"measure": "Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)", "description": "Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (\\< 24 hours); Hospital admission or Emergency department visit (\\> 24 hours).", "timeFrame": "Week 4, Week 12, and Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Written informed consent, and assent if applicable, must be obtained before any assessment is performed.\n2. Male or female patients 12 years of age and older\n3. Confirmed diagnosis of persistent asthma, as defined by national and international asthma guidelines (e.g., GINA; NIH; etc.) for at least 1 year prior to study enrollment.\n4. PEF\u226550% of predicted normal value.\n5. Current and appropriate use of one of the treatments listed in the protocol for asthma.\n6. Recent asthma exacerbation between 30 days and 12 months prior to randomization that either:\n\n   * required treatment with systemic corticosteroids (tablets, suspension, or injection) or\n   * required hospitalization (defined as an inpatient stay or \\>24-hour stay in an observation area in an emergency room or other equivalent facility)\n\nKey Exclusion Criteria:\n\n1. History of life-threatening asthma episode that required intubation and/or was associated with hypercapnia requiring non-invasive ventilatory support.\n2. Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other respiratory abnormalities other than asthma.\n3. Current evidence of, or past physician assessment of, chronic bronchitis, emphysema, or chronic obstructive pulmonary disease.\n4. History of smoking \u2265 10 pack years.\n5. Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine.\n6. Suspected or documented bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved at randomization.\n7. Worsening/Unstable asthma within 7 days prior to randomization.\n8. Any asthma exacerbation requiring systemic corticosteroids within 30 days of randomization or more than 4 separate exacerbations in the 12 months preceding randomization.\n9. Two or more hospitalizations for greater than 24 hours duration for treatment of asthma in the 12 months preceding randomization.\n10. History of hypersensitivity to any beta2-agonist, sympathomimetic drug, inhaled corticosteroids, or systemic corticosteroid therapy or any component of the possible study treatments in this trial, including severe milk protein hypersensitivity.\n11. Use of anti-IgE (e.g., omalizumab) or any other monoclonal antibody, in the 6 months prior to randomization.\n12. Use of (Beta) \u03b2-blockers within 1 day prior to first dose of study medication.\n13. Use of ICS, LABA, ICS+LABA, LTRAs, leukotriene modifiers, anticholinergics, or theophylline must be discontinued prior to the first dose of investigational treatment.\n14. Use of a potent CYP3A4 inhibitor within 4 weeks of randomization (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Chrsitopher Compton", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Avondale", "state": "Arizona", "zip": "85323", "country": "United States", "geoPoint": {"lat": 33.4356, "lon": -112.3496}}, {"facility": "Novartis Investigative Site", "city": "North Hollywood", "state": "California", "zip": "91606", "country": "United States", "geoPoint": {"lat": 34.17223, "lon": -118.37897}}, {"facility": "Novartis Investigative Site", "city": "Bradenton", "state": "Florida", "zip": "34209", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"facility": "Novartis Investigative Site", "city": "Miami", "state": "Florida", "zip": "33126", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novartis Investigative Site", "city": "Miami", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novartis Investigative Site", "city": "Conyers", "state": "Georgia", "zip": "30012", "country": "United States", "geoPoint": {"lat": 33.66761, "lon": -84.01769}}, {"facility": "Novartis Investigative Site", "city": "Stone Mountain", "state": "Georgia", "zip": "30083", "country": "United States", "geoPoint": {"lat": 33.80816, "lon": -84.1702}}, {"facility": "Novartis Investigative Site", "city": "Louisville", "state": "Kentucky", "zip": "40214", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Novartis Investigative Site", "city": "Louisville", "state": "Kentucky", "zip": "40220", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Novartis Investigative Site", "city": "Covington", "state": "Louisiana", "zip": "70433", "country": "United States", "geoPoint": {"lat": 30.47549, "lon": -90.10042}}, {"facility": "Novartis Investigative Site", "city": "Baltimore", "state": "Maryland", "zip": "21287", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novartis Investigative Site", "city": "Gaithersburg", "state": "Maryland", "zip": "20878", "country": "United States", "geoPoint": {"lat": 39.14344, "lon": -77.20137}}, {"facility": "Novartis Investigative Site", "city": "Picayune", "state": "Mississippi", "zip": "39466", "country": "United States", "geoPoint": {"lat": 30.52556, "lon": -89.67788}}, {"facility": "Novartis Investigative Site", "city": "Saint Louis", "state": "Missouri", "zip": "63117", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Saint Louis", "state": "Missouri", "zip": "63128", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "North Massapequa", "state": "New York", "zip": "11758", "country": "United States", "geoPoint": {"lat": 40.70093, "lon": -73.46207}}, {"facility": "Novartis Investigative Site", "city": "Elizabeth City", "state": "North Carolina", "zip": "27909", "country": "United States", "geoPoint": {"lat": 36.2946, "lon": -76.25105}}, {"facility": "Novartis Investigative Site", "city": "Winston Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Novartis Investigative Site", "city": "Cleveland", "state": "Ohio", "zip": "44106-5000", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Novartis Investigative Site", "city": "Oaks", "state": "Pennsylvania", "zip": "19456", "country": "United States", "geoPoint": {"lat": 40.13177, "lon": -75.45963}}, {"facility": "Novartis Investigative Site", "city": "East Greenwich", "state": "Rhode Island", "zip": "02818", "country": "United States", "geoPoint": {"lat": 41.66038, "lon": -71.45589}}, {"facility": "Novartis Investigative Site", "city": "Mount Pleasant", "state": "South Carolina", "zip": "29464", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"facility": "Novartis Investigative Site", "city": "Memphis", "state": "Tennessee", "zip": "38118", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Novartis Investigative Site", "city": "Dallas", "state": "Texas", "zip": "75235", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novartis Investigative Site", "city": "Saint George", "state": "Utah", "zip": "84790", "country": "United States", "geoPoint": {"lat": 37.10415, "lon": -113.58412}}, {"facility": "Novartis Investigative Site", "city": "Mequon", "state": "Wisconsin", "zip": "53092", "country": "United States", "geoPoint": {"lat": 43.21573, "lon": -88.02962}}, {"facility": "Novartis Investigative Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53172", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "827 actual in the protocol section came from the IRT because 2 patients were randomized twice but only counted once.", "recruitmentDetails": "Following the decision to stop further enrollment into the study, 1121 patients had been screened, of whom 825 were randomized. Of the 820 patients randomized and treated and part of Intent To Treat (ITT analysis) 5 patients were randomized but were excluded from the ITT analyses as they did not take study medication.", "groups": [{"id": "FG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "FG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "411"}, {"groupId": "FG001", "numSubjects": "409"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "326"}, {"groupId": "FG001", "numSubjects": "332"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "77"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Missing", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "BG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "411"}, {"groupId": "BG001", "value": "409"}, {"groupId": "BG002", "value": "820"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.7", "spread": "16.67"}, {"groupId": "BG001", "value": "45.6", "spread": "17.02"}, {"groupId": "BG002", "value": "45.2", "spread": "16.84"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "284"}, {"groupId": "BG001", "value": "272"}, {"groupId": "BG002", "value": "556"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "137"}, {"groupId": "BG002", "value": "264"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks", "description": "The primary safety endpoint was the number of first occurrence(s) of any composite endpoint. The composite events include asthma-related deaths, asthma-related intubations and asthma-related hospitalizations. The number of events includes all adjudication confirmed events, one patient could experience multiple events during the course of study; Event rate = 100 \\* n patients with any events / total N patients in treatment group.", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "number of occurences", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"title": "Composite event", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Asthma-related death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Asthma-related intubation", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Asthma-related hospitalization", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}]}]}, {"type": "SECONDARY", "title": "Number of Asthma Exacerbations at 26 Weeks", "description": "Number of asthma exacerbations events", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "events", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "0.62"}, {"groupId": "OG001", "value": "1.2", "spread": "0.51"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Days of School/Work Missed at 26 Weeks", "description": "The percentage of days of school/work missed during the treatment period (26 weeks). Overall percentage of school days missed for each student patient or of work days missed is calculated by total number of days missed divided by total days of treatment.", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.97", "spread": "4.558"}, {"groupId": "OG001", "value": "0.56", "spread": "1.641"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Days With Limited Ability to Perform Normal Daily Activities at 26 Weeks", "description": "The percentage of days with limited ability to perform normal daily activities during the treatment period (26 weeks). Percentage is calculated as total number of days when the patient had limited ability to perform normal daily activities divided by total days of treatment.", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.73", "spread": "12.774"}, {"groupId": "OG001", "value": "4.75", "spread": "12.705"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Days With Nighttime Awakenings at 26 Weeks", "description": "Percentage of days with nighttime awakenings during the treatment period (26 weeks)", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.55", "spread": "9.577"}, {"groupId": "OG001", "value": "4.20", "spread": "8.956"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Days With no Rescue Medication Use at 26 Weeks", "description": "Percentage of rescue free days is calculated as total number of days with no rescue medication was taken divided by total days of treatment.", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "76.97", "spread": "27.255"}, {"groupId": "OG001", "value": "73.29", "spread": "30.640"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Days With no Symptoms at 26 Weeks", "description": "Percentage of days with no symptoms during the treatment period (26 weeks). Percentage is calculated as total number of days with no symptoms divided by total days of treatment.", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of days", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "79.47", "spread": "25.501"}, {"groupId": "OG001", "value": "77.64", "spread": "28.394"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ - 6) Total Score at Week 26", "description": "Change from baseline in Asthma control Questionnaire (ACQ - 6) total score at week 26. Results of the Asthma control questionnaire (ACQ-6); The average score of the six questions is calculated as the sum of scores divided by the number of questions that were answered at the time point, as long as there were at least 4 questions answered. The ACQ6 score is calculated as the mean of the responses to the first 6 questions of the ACQ. The ACQ is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a total score of 0 corresponds to no impairment and a total score of 6 corresponds to maximum impairment.", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "total score on a scale", "timeFrame": "baseline and 26 weeks", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.65", "spread": "1.224"}, {"groupId": "OG001", "value": "-0.59", "spread": "1.094"}]}]}]}, {"type": "SECONDARY", "title": "Unplanned Healthcare Utilization at Visit 3 (Week 4), Visit 4 (Week 12) and Visit 5 (Week 26)", "description": "Unplanned healthcare utilization by visit (Telephone contact with study doctor (MD); Telephone contact with other physician (MD) or healthcare provider (HCP); Unscheduled or unplanned visit to study doctor (including home visits); Unscheduled or unplanned visit to other physician or healthcare provider (including home visits); Emergency department or hospital visit (\\< 24 hours); Hospital admission or Emergency department visit (\\> 24 hours).", "populationDescription": "Intent to treat (ITT) population included all randomized patients who took at least one dose (one inhalation) of study medication", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "unplanned visits", "timeFrame": "Week 4, Week 12, and Week 26", "groups": [{"id": "OG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation"}, {"id": "OG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "411"}, {"groupId": "OG001", "value": "409"}]}], "classes": [{"title": "Telephone contact with study MD: V3", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Telephone contact with other MD or HCP: V3", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "unplanned visit to study MD;include home:V3", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "unplanned visit to other MD or HCP incl.home:V3", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Emergency or hospital visit (< 24 hours):V3", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Hospital admission or Emergency visit (>24hrs):V3", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Telephone contact with study MD: V4", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "17"}]}]}, {"title": "Telephone contact with other MD or HCP: V4", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "unplanned visit to study MD;include home:V4", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": "unplanned visit to other MD or HCP incl.home:V4", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Emergency or hospital visit (< 24 hours):V4", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "Hospital admission or Emergency visit (>24hrs):V4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Telephone contact with study MD: V5", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Telephone contact with other MD or HCP: V5", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "unplanned visit to study MD;include home:V5", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "unplanned visit to other MD or HCP incl.home:V5", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Emergency or hospital visit (< 24 hours):V5", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Hospital admission or Emergency visit (>24hrs):V5", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "FOM 12 mcg + FP", "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation", "seriousNumAffected": 10, "seriousNumAtRisk": 411, "otherNumAffected": 5, "otherNumAtRisk": 411}, {"id": "EG001", "title": "Fluticasone Propionate (FP)", "description": "fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation", "seriousNumAffected": 9, "seriousNumAtRisk": 409, "otherNumAffected": 9, "otherNumAtRisk": 409}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Duodenal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Tracheobronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Alcohol poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Breast cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Dyskinesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 409}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 409}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 409}]}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 411}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 409}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}]}}, "hasResults": true}